Maze Therapeutics 计划在 IPO 中筹集 $125M，针对肾脏、心脏和代谢疾病。 Maze Therapeutics plans to raise $125M in an IPO, targeting kidney, heart, and metabolic diseases.

迷宫治疗公司计划在2025年1月31日进行首次公开募股,旨在通过发行价格在15美元至17美元之间的780万股股票来筹集1.25亿美元. Maze Therapeutics plans an IPO on January 31, 2025, aiming to raise $125 million by issuing 7.8 million shares priced between $15 and $17 each. 该公司的市场上限为6.852亿美元,侧重于开发用于肾、心脏和代谢疾病的精密药品。 The company, with a market cap of $685.2 million, focuses on developing precision medicines for kidney, heart, and metabolic diseases. Maze治疗机构利用其指南针平台查明与疾病有关的遗传变异,推进两个针对慢性肾病的牵头方案。 Maze Therapeutics uses its Compass platform to identify genetic variants linked to diseases, advancing two lead programs targeting chronic kidney disease. IPO由J. P. Morgan、TD Cowen、Leerink和Guggenheim证券公司担保。 The IPO is underwritten by J.P. Morgan, TD Cowen, Leerink, and Guggenheim Securities.